Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,055 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
Ji L, Dong X, Li Y, Li Y, Lim S, Liu M, Ning Z, Rasmussen S, Skjøth TV, Yuan G, Eliaschewitz FG. Ji L, et al. Among authors: yuan g. Diabetes Obes Metab. 2021 Feb;23(2):404-414. doi: 10.1111/dom.14232. Epub 2021 Jan 3. Diabetes Obes Metab. 2021. PMID: 33074557 Free PMC article. Clinical Trial.
Improvement of β-cell function ameliorated glycemic variability in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion or in combination with sitagliptin treatment: a randomized control trial.
Yuan G, Hu H, Wang S, Yang Q, Yu S, Sun W, Qian W, Mao C, Zhou L, Chen D, Wang Z, Gong Q, Wang D. Yuan G, et al. Endocr J. 2015;62(9):817-34. doi: 10.1507/endocrj.EJ15-0160. Epub 2015 Jul 18. Endocr J. 2015. PMID: 26194272 Free article. Clinical Trial.
[The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial].
Mu YM, Guo LX, Li L, Li YM, Xu XJ, Li QM, Xu MT, Zhu LY, Yuan GY, Liu Y, Xu C, Wang ZJ, Shen FX, Luo Y, Liu JY, Li QF, Wang WH, Lai XY, Xu HF, Pan CY. Mu YM, et al. Among authors: yuan gy. Zhonghua Nei Ke Za Zhi. 2017 Sep 1;56(9):660-666. doi: 10.3760/cma.j.issn.0578-1426.2017.09.008. Zhonghua Nei Ke Za Zhi. 2017. PMID: 28870034 Clinical Trial. Chinese.
Determining the optimal fasting glucose target for patients with type 2 diabetes: Results of the multicentre, open-label, randomized-controlled FPG GOAL trial.
Yang W, Ma J, Yuan G, Li L, Zhang M, Lu Y, Ye X, Song W, Liu M, Wu J, Chen R, Li Y, Zhang X, Cui N, Yang J. Yang W, et al. Among authors: yuan g. Diabetes Obes Metab. 2019 Aug;21(8):1973-1977. doi: 10.1111/dom.13733. Epub 2019 Jun 10. Diabetes Obes Metab. 2019. PMID: 30938035 Free PMC article. Clinical Trial.
Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naïve people with type 2 diabetes: The EDITION AP randomized controlled trial.
Ji L, Kang ES, Dong X, Li L, Yuan G, Shang S, Niemoeller E; EDITION AP trial investigators. Ji L, et al. Among authors: yuan g. Diabetes Obes Metab. 2020 Apr;22(4):612-621. doi: 10.1111/dom.13936. Epub 2019 Dec 26. Diabetes Obes Metab. 2020. PMID: 31797549 Free PMC article. Clinical Trial.
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Yang W, Dong X, Li Q, Cheng Z, Yuan G, Liu M, Xiao J, Gu S, Niemoeller E, Chen L, Ping L, Souhami E; LixiLan-O-AP trial investigators. Yang W, et al. Among authors: yuan g. Diabetes Obes Metab. 2022 Aug;24(8):1522-1533. doi: 10.1111/dom.14722. Epub 2022 May 12. Diabetes Obes Metab. 2022. PMID: 35441412 Clinical Trial.
3,055 results